NEW YORK (360Dx) – NMDX today announced deals to expand the availability and use of the firm's HER-2/neu test.
In one deal, NMDX has retained Martell Diagnostic Laboratories to run tests on certain patient serum samples provided by NMDX. Martell, which has a CLIA-certified laboratory, will purchase HER-2 assay kits from NMDX for development and clinical use for testing for its own projects and for clinical testing of NMDX patient samples. For its lab testing service, Martell will use the NMDX HER-2/neu ELISA assay to quantitate human HER-2/neu levels to monitor metastatic breast cancer in women, NMDX said.
Separately, the company is granting Immuno-Biological Laboratories a non-exclusive right to sell NMDX's products, including the IVD HER-2/neu ELISA and selected antibodies. Other NMDX products may also be part of the deal at the firm's discretion, NMDX said.
Both agreements take effect this month. Further details were not disclosed.
NMDX, which also goes by the name NanoMolecularDx, was founded by Patrick Muraca after Nuclea Biotechnologies closed shop and Muraca, the founder and former CEO of Nuclea, bought its assets.